

CLAIMS

1. Use of ZD6126 or a pharmaceutically acceptable salt thereof and one of:
 - a) 5-FU;
 - 5 b) CPT-11; and
 - c) 5-FU and CPT-11,in the manufacture of a medicament for use in the production of a vascular damaging effect in a warm-blooded animal.
- 10 2. Use according to claim 1 for use in the production of an anti-tumour effect in a warm-blooded animal.
3. Use according to claim 1 for use in the production of an anti-cancer effect in a warm-blooded animal.
- 15 4. Use according to claim 1 for use in the treatment of a cancer involving a solid tumour in a warm-blooded animal.
5. Use according to claim 4 wherein the cancer is colorectal cancer.
- 20 6. Use according to any one of the preceding claims wherein the ZD6126 or a pharmaceutically acceptable salt thereof is used with 5-FU.
7. Use according to any one of claims 1 to 5 wherein the ZD6126 or a pharmaceutically acceptable salt thereof is used with CPT-11.
- 25 8. Use according to any one of claims 1 to 5 wherein the ZD6126 or a pharmaceutically acceptable salt thereof is used with 5-FU and CPT-11.
- 30 9. Use according to any one of the preceding claims wherein the warm-blooded animal is being treated with ionising radiation.

10. Use according to any one of the preceding claims wherein the ZD6126 or a pharmaceutically acceptable salt thereof is administered to the warm-blooded animal in divided doses.
- 5 11. Use according to any one of claims 1 to 6 wherein the 5-FU is administered to the warm-blooded animal in the form of a prodrug of 5-FU.
12. A pharmaceutical composition comprising ZD6126 or a pharmaceutically acceptable salt thereof, and 5-FU in association with a pharmaceutically acceptable excipient or carrier.
- 10 13. A pharmaceutical composition comprising ZD6126 or a pharmaceutically acceptable salt thereof, and CPT-11 in association with a pharmaceutically acceptable excipient or carrier.
14. A pharmaceutical composition comprising ZD6126 or a pharmaceutically acceptable salt thereof, and 5-FU and CPT-11 in association with a pharmaceutically acceptable excipient or carrier.
- 15 15. A kit comprising ZD6126 or a pharmaceutically acceptable salt thereof, and 5-FU.
- 20 16. A kit comprising ZD6126 or a pharmaceutically acceptable salt thereof, and CPT-11.
17. A kit comprising ZD6126 or a pharmaceutically acceptable salt thereof, and 5-FU and CPT-11.
- 25 18. A method for the production of a vascular damaging effect in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6126 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of one of:
- a) 5-FU;
- 30 b) CPT-11; and
- c) 5-FU and CPT-11.

19. A method for the treatment of a cancer involving a solid tumour in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6126 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of one of:

- 5 a) 5-FU;
 b) CPT-11; and
 c) 5-FU and CPT-11.

20. A method according to claim 19 wherein the cancer is colorectal cancer.

10

21. A method according to any one of claims 18 to 20 wherein the ZD6126 or a pharmaceutically acceptable salt thereof is administered before, after or simultaneously with an effective amount of 5-FU.

15 22. A method according to any one of claims 18 to 20 wherein ZD6126 or a pharmaceutically acceptable salt thereof is administered before, after or simultaneously with an effective amount of CPT-11.

23. A method according to any one of claims 18 to 20 wherein ZD6126 or a pharmaceutically
20 acceptable salt thereof is administered before, after or simultaneously with an effective amount of 5-FU, and before, after or simultaneously with an effective amount of CPT-11.

24. A method according to any one claims 18 to 20 further comprising administration to said warm-blooded animal an effective amount of ionising radiation, wherein the ZD6126, ionising
25 radiation, 5-FU and/or CPT-11 are administered simultaneously, sequentially or separately in any order.

25. A method according to any one of claims 18 to 20 wherein the ZD6126 or a pharmaceutically acceptable salt thereof, is administered to said warm-blooded animal in
30 divided doses.

26. A method according to any one of claims 18 to 21 wherein the 5-FU is administered to said warm-blooded animal in the form of a prodrug of 5-FU.